Equities research analysts at HC Wainwright upped their FY2024 earnings per share (EPS) estimates for shares of Black Diamond ...
Mustang Bio has received orphan drug designation from the US Food and Drug Administration (FDA) for MB-108, a herpes simplex ...
Announced encouraging initial Phase 2 data of BDTX-1535 in patients with recurrent EGFRm NSCLC with a broad spectrum of classical, non-classical, ...
seekingalpha.com reported 2024-10-08 that Preliminary results from phase 2 study using BDTX-1535 for the treatment of 1st-line EGFRm NSCLC patients, expected in Q1 of 2025. Updated cohort results from ...
In head-to-head comparisons with firmonertinib, zipalertinib, lazertinib and BDTX-1535, ORIC-114 has superior kinome selectivity with no off-target kinase liabilities identified. Shows complete ...
seekingalpha.com reported 2024-10-08 that Preliminary results from phase 2 study using BDTX-1535 for the treatment of 1st-line EGFRm NSCLC patients, expected in Q1 of 2025. Updated cohort results from ...
BDTX-1535 has demonstrated robust Phase 2 clinical activity across a broad spectrum of epidermal growth factor receptor mutations (EGFRm) in patients with recurrent non-small cell lung cancer (NSCLC).
The company's lead product candidate is BDTX-1535, a brain-penetrant epidermal growth factor receptor MasterKey inhibitor, which is in phase 2 clinical trial for the treatment of epidermal growth ...
and BDTX-1535. Additionally, evidence of molecular response in ctDNA from patients whose tumors harbored PACC mutations and exon 20 insertion mutations was observed with ORIC-114 treatment. ORIC-114 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback